Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

755
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

267
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
267
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

506
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
506

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Lipid-lowering therapy after finding high Lp(a)-adding ezetimibe or intensifying statin treatment?

Journal of clinical lipidology·2026
Same author

Genetic determinants of childhood blood pressure and heart rate in relation to adult health outcomes: the consortium of childhood blood pressure.

European heart journal·2026
Same author

Brain magnetic resonance imaging biomarkers for future frailty; sub-study of FINGER trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control.

Lipids in health and disease·2026
Same author

Mechanistic explanation for the different statin response according to APOE genotypes.

British journal of clinical pharmacology·2026

関連する実験動画

Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

75歳以上を対象とした単剤エゼチミブによる心血管イベント抑制の一次予防

Alpo Vuorio1,2, Petri T Kovanen3, Timo Strandberg4,5

  • 1Mehiläinen, Aviapolis Health Center, Vantaa, Finland.

Annals of medicine
|February 24, 2026
PubMed
まとめ
この要約は機械生成です。

EWTOPIA 75スタディは、エゼチミブが心疾患の既往がない高齢者のアテローム性心血管疾患(ASCVD)イベントを減少させることを示している。このコレステロール吸収阻害薬は、加齢に伴う変化と良好な副作用プロファイルにより、有益性をもたらす可能性がある。

キーワード:
ASCVD吸収NPC1L1遺伝子コレステロールエゼチミブ高齢者

さらに関連する動画

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

関連する実験動画

Last Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

科学分野:

  • 循環器病学
  • 老年医学
  • 薬理学

背景:

  • アテローム性心血管疾患(ASCVD)は、特に高齢者において、罹患および死亡の主要な原因であり続けている。
  • コレステロール管理は重要であるが、スタチン療法はすべての人々、特に高齢者には適していないか、または十分ではない可能性がある。
  • EWTOPIA 75スタディは、75歳以上の個人におけるASCVDの一次予防におけるエゼチミブの有効性を調査した。

主な方法:

  • EWTOPIA 75スタディには、確立されたASCVDを持たない75歳以上の参加者が含まれた。
  • ASCVDイベントリスクに対する影響を評価するために、エゼチミブが単剤療法として投与された。
  • 研究デザインは一次予防の結果に焦点を当てた。

結論:

  • エゼチミブ単剤療法は、冠動脈疾患の既往がない75歳以上の個人におけるASCVDリスクを減少させるのに有効である。
  • 加齢に伴うコレステロール吸収の増加は、この集団におけるエゼチミブの有効性を高める可能性がある。
  • エゼチミブの良好な安全性プロファイルとより良好なアドヒアランスの可能性は、高齢者のASCVD一次予防において考慮に値する。